ArticleInfection2018
Invasive fungal infections associated with prior respiratory viral infections in immunocompromised hosts.
Article in Infection, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Clinical Features and Mortality of COVID-19-Associated Mucormycosis: A Systematic Review and Meta-Analysis.Mycopathologia · 2022Pooled it
- Pooled it
- The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.Frontiers in nutrition · 2025Article
- Article
- Risk Factors and Environmental Preventive Actions for Aspergillosis in Patients with Hematological Malignancies.Clinics and practice · 2024Review
- Association between the cumulative dose of glucocorticoids before the development of pneumonia and death in patients receiving long-term glucocorticoids: a secondary analysis based on a Chinese cohort study.Frontiers in medicine · 2023Article
- Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Pulmonary Aspergillosis in Critically Ill Patients: A Nationwide, Multicenter, Retrospective Cohort Study.Journal of Korean medical science · 2022Article
- COVID-19 associated mucormycosis - An emerging threat.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2022Review
- When Viruses Meet Fungi: Tackling the Enemies in Hematology.Journal of fungi (Basel, Switzerland) · 2022Review
- Predisposing factors of important invasive fungal coinfections in COVID-19 patients: a review article.The Journal of international medical research · 2021Review
- Invasive Aspergillosis After Influenza and Other Viral Respiratory Infections Among Intensive Care Unit Patients in a Commercially Insured Population in the United States, 2013-2018.Open forum infectious diseases · 2021Article
- A Novel Diagnostic Method for Invasive Fungal Disease Using the Factor G Alpha Subunit FromFrontiers in microbiology · 2021Article
- A family cluster of diagnosed coronavirus disease 2019 (COVID-19) kidney transplant recipient in Thailand.Immunity, inflammation and disease · 2020Article
- Article
- Invasive Pulmonary Aspergillosis in Patients with SARS-CoV-2 Infection: A Systematic Review of the Literature.Diagnostics (Basel, Switzerland) · 2020Review
- A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient.Medical mycology case reports · 2020Article
- Invasive Fungal Carotiditis: A Rare Manifestation of Cranial Invasive Fungal Disease: Case Series and Systematic Review of the Literature.Open forum infectious diseases · 2019Article
- Outcomes in Invasive Pulmonary Aspergillosis Infections Complicated by Respiratory Viral Infections in Patients With Hematologic Malignancies: A Case-Control Study.Open forum infectious diseases · 2019Article
- Influenza virus and factors that are associated with ICU admission, pulmonary co-infections and ICU mortality.Journal of critical care · 2019Article
- First isolation ofNew microbes and new infections · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundIncreased risk of invasive pulmonary aspergillosis after influenza infection has been reported; however data are limited. PURPOSE: To describe Invasive fungal infections (IFI) associated with preceding respiratory viral infection at a large referral center.
methodsWe reviewed all IFI cases among patients with positive influenza and/or RSV nasopharyngeal/lower respiratory tract PCR from October 2015 to December 2016. Cases of pulmonary IFI were classified as possible, probable, and definite based on EORTC-MSG definitions.
resultsWe identified 8 cases (4 influenza, 4 RSV); 3 with probable Aspergillosis, 1 possible Aspergillosis, 1 probable Histoplasmosis, 1 probable Mucormycosis, and 2 possible IFI (consistent clinical and imaging findings). Half of our patients were men with a mean age of 64 years (SD 8) and median Charlson Comorbidity Score of 3.5 (IQR 3-7). Most common risk factors were stem cell transplant (75%) and neutropenia (62.5%). Four patients were on antifungal prophylaxis at presentation. All patients received anti-viral therapy with oseltamivir/ribavirin and 50% received empiric antibiotics. Median duration from onset of viral infection to diagnosis of IFI was 8.5 days (IQR 2.5-14) and 75% were diagnosed during the same admission. All received antifungal therapy; 62.5% required ICU care, and 37.5% died during index hospitalization.
conclusionsOur study supports earlier observations describing IFI following respiratory viral infection in immunocompromised hosts. Secondary IFI occurred in 1.4% of our cohort and most occurred during the index admission. IFI following viral illness is associated with high mortality and early detection and therapy may improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.